

2021-22 exceptional surveillance of familial breast cancer (NICE guideline CG164)

Surveillance proposal

We propose to withdraw recommendation 1.1.2 from the guideline on [familial breast cancer](#).

No other recommendations are affected by this proposal.

Background

NICE was contacted by a stakeholder and asked to withdraw recommendation 1.1.2 from [familial breast cancer](#). The recommendation states:

- Healthcare professionals should respond to a person who presents with concerns but should not, in most instances, actively seek to identify people with a family history of breast cancer.

NICE surveillance check

The NICE surveillance team checked the guideline to see if there would be any unintended consequences of removing the recommendation.

The review concluded that there is no documented justification for the recommendation within the full guideline – it was not directly linked to evidence or committee discussion - and the intention of the recommendation in the context of the section on family history-taking in primary care is unclear and redundant. It was also identified that removing the recommendation would have no detriment to the guideline's primary care algorithm, which can be found in the [full guideline](#) on page 40.

Information for stakeholders

For further details about the process and the possible update decisions that are available and our consultation processes, see [ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual](#).

Because we are proposing to withdraw recommendations from the guideline we are consulting stakeholders.

Equalities

No equalities issues were identified during the surveillance process.

Overall surveillance proposal

We propose to withdraw recommendation 1.1.2 from the guideline on familial breast cancer.

No other recommendations are affected by this proposal.